Form D · Other Health Care
ASCELLA BIOSYSTEMS, INC.
San Francisco, CA · CIK 0002006111
Offering snapshot reported Dec 28, 2023 · SEC filing
- Reported sold
- $6.33M Offering amount: $6.33M
- Investors reported
- 11 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 18, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 28, 2023 | Initial | $6,331,965 | No comparison | 11 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-501010
Source: Form D, filed Dec 28, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Deepak Boggavarapu | Director, Executive, Promoter |
| Satoru Iino | Director |
| Junichi Kajimoto | Director, Executive |
Issuer details
Industry: Other Health Care (See others in industry)
Address:
150 Hooper Street, Suite 212
San Francisco, CA, 94107
San Francisco, CA, 94107